STOCK TITAN

[Form 4] CAVA Group, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 Overview – Vita Coco Company, Inc. (COCO)

Chief Marketing Officer Jane Prior reported a paired option exercise and share sale dated 06/18/2025. She exercised 10,000 non-qualified stock options at an exercise price of $10.178 per share (transaction code “M”), immediately acquiring the same number of common shares. On the same day she sold 10,000 shares in the open market under a pre-arranged Rule 10b5-1 trading plan (transaction code “S”) at a weighted-average price of $35.116, within a range of $35.00–$35.33. After the transactions, Prior’s direct common-stock holding remains at 134,188 shares, unchanged on a net basis.

The filing also details Prior’s remaining derivative exposure: 169,479 vested and unvested options across eight grants with strike prices from $10.178 to $33.36 and expirations spanning 02/10/2030–03/04/2035. Of these, 63,750 options (strike $10.178) are now reduced by 10,000, reflecting the exercise. Vesting schedules for later grants extend through August 2032 and March 2035, ensuring a continued alignment of incentive compensation with long-term share performance.

Because the share sale offsets the option exercise, Prior’s economic exposure through common equity is unchanged; however, her derivative exposure decreased modestly. The use of a Rule 10b5-1 plan signals pre-planned execution, potentially mitigating signaling risk. No other insiders or directors were involved, and the filing lists no new option awards or share acquisitions beyond those described.

Panoramica del Modulo 4 – Vita Coco Company, Inc. (COCO)

La Chief Marketing Officer Jane Prior ha comunicato un esercizio abbinato di opzioni e una vendita di azioni datata 18/06/2025. Ha esercitato 10.000 opzioni su azioni non qualificate a un prezzo di esercizio di 10,178 $ per azione (codice transazione “M”), acquisendo immediatamente lo stesso numero di azioni ordinarie. Nello stesso giorno ha venduto 10.000 azioni sul mercato aperto nell’ambito di un piano di trading predefinito ai sensi della Regola 10b5-1 (codice transazione “S”) a un prezzo medio ponderato di 35,116 $, in un intervallo da 35,00 $ a 35,33 $. Dopo le transazioni, la detenzione diretta di azioni ordinarie di Prior rimane invariata a 134.188 azioni, senza variazioni nette.

Il documento dettaglia inoltre l’esposizione residua di Prior in strumenti derivati: 169.479 opzioni, sia maturate che non maturate, distribuite su otto concessioni con prezzi di esercizio compresi tra 10,178 $ e 33,36 $ e scadenze dal 10/02/2030 al 04/03/2035. Di queste, 63.750 opzioni (prezzo di esercizio 10,178 $) sono state ridotte di 10.000 in seguito all’esercizio. I piani di maturazione delle concessioni successive si estendono fino ad agosto 2032 e marzo 2035, garantendo un allineamento continuo della remunerazione incentivante con la performance azionaria a lungo termine.

Poiché la vendita delle azioni compensa l’esercizio delle opzioni, l’esposizione economica di Prior tramite il capitale ordinario rimane invariata; tuttavia, la sua esposizione derivata è diminuita leggermente. L’utilizzo di un piano secondo la Regola 10b5-1 indica un’esecuzione pianificata in anticipo, potenzialmente riducendo il rischio di segnali negativi. Nessun altro dirigente o amministratore è stato coinvolto e il documento non riporta nuove assegnazioni di opzioni né acquisizioni di azioni oltre a quelle descritte.

Resumen del Formulario 4 – Vita Coco Company, Inc. (COCO)

La Directora de Marketing Jane Prior reportó un ejercicio combinado de opciones y venta de acciones fechado el 18/06/2025. Ella ejerció 10,000 opciones sobre acciones no calificadas a un precio de ejercicio de $10.178 por acción (código de transacción “M”), adquiriendo inmediatamente la misma cantidad de acciones ordinarias. Ese mismo día vendió 10,000 acciones en el mercado abierto bajo un plan de trading preestablecido conforme a la Regla 10b5-1 (código de transacción “S”) a un precio promedio ponderado de $35.116, dentro de un rango de $35.00 a $35.33. Tras las transacciones, la tenencia directa de acciones ordinarias de Prior permanece en 134,188 acciones, sin cambios netos.

El informe también detalla la exposición restante de Prior en derivados: 169,479 opciones, tanto ejercibles como no ejercibles distribuidas en ocho concesiones con precios de ejercicio desde $10.178 hasta $33.36 y vencimientos entre el 10/02/2030 y el 04/03/2035. De estas, 63,750 opciones (precio de ejercicio $10.178) se redujeron en 10,000 debido al ejercicio. Los calendarios de adquisición de las concesiones posteriores se extienden hasta agosto de 2032 y marzo de 2035, asegurando una alineación continua de la compensación por incentivos con el rendimiento accionarial a largo plazo.

Dado que la venta de acciones compensa el ejercicio de opciones, la exposición económica de Prior a través del capital común no cambia; sin embargo, su exposición en derivados disminuyó modestamente. El uso de un plan conforme a la Regla 10b5-1 indica una ejecución planificada, lo que podría mitigar riesgos de señales negativas. Ningún otro directivo o director estuvo involucrado y el informe no menciona nuevas concesiones de opciones ni adquisiciones de acciones más allá de las descritas.

Form 4 개요 – Vita Coco Company, Inc. (COCO)

최고마케팅책임자 Jane Prior는 2025년 6월 18일자로 옵션 행사와 주식 매도 거래를 보고했습니다. 그녀는 10,000개의 비자격 주식매수선택권을 행사하였으며, 행사 가격은 주당 10.178달러였습니다(거래 코드 “M”). 즉시 동일 수량의 보통주를 취득했습니다. 같은 날, 그녀는 10,000주를 사전 계획된 Rule 10b5-1 거래계획에 따라 공개 시장에서 매도하였으며(거래 코드 “S”), 가중평균 가격은 35.116달러, 가격 범위는 35.00달러에서 35.33달러였습니다. 거래 후 Prior의 직접 보유 보통주 수는 134,188주로 순변동 없이 유지되었습니다.

보고서에는 Prior의 남은 파생상품 노출도 상세히 명시되어 있습니다: 8건의 부여를 통해 169,479개의 행사 가능 및 행사 불가능 옵션이 있으며, 행사가격은 10.178달러에서 33.36달러 사이이고 만료일은 2030년 2월 10일부터 2035년 3월 4일까지입니다. 이 중 63,750개 옵션(행사가격 10.178달러)은 행사로 인해 10,000개가 감소했습니다. 이후 부여된 옵션의 권리 취득 일정은 2032년 8월과 2035년 3월까지 이어져 장기 주가 성과와 인센티브 보상 간의 지속적인 정렬을 보장합니다.

주식 매도가 옵션 행사와 상쇄되었기 때문에 Prior의 보통주를 통한 경제적 노출은 변동이 없습니다; 다만 파생상품 노출은 다소 감소했습니다. Rule 10b5-1 계획의 사용은 사전 계획된 실행을 의미하며, 신호 위험 완화에 기여할 수 있습니다. 다른 임원이나 이사는 관여하지 않았으며, 보고서에는 본문에 설명된 것 외에 새로운 옵션 부여나 주식 취득 내역이 없습니다.

Présentation du Formulaire 4 – Vita Coco Company, Inc. (COCO)

La Directrice Marketing Jane Prior a déclaré une opération combinée d’exercice d’options et de vente d’actions datée du 18/06/2025. Elle a exercé 10 000 options d’achat d’actions non qualifiées à un prix d’exercice de 10,178 $ par action (code transaction « M »), acquérant immédiatement le même nombre d’actions ordinaires. Le même jour, elle a vendu 10 000 actions sur le marché libre dans le cadre d’un plan de trading préétabli selon la règle 10b5-1 (code transaction « S ») à un prix moyen pondéré de 35,116 $, dans une fourchette de 35,00 $ à 35,33 $. Après ces opérations, la détention directe d’actions ordinaires de Prior reste à 134 188 actions, inchangée sur une base nette.

Le dépôt détaille également l’exposition résiduelle de Prior aux dérivés : 169 479 options, acquises et non acquises, réparties sur huit attributions avec des prix d’exercice allant de 10,178 $ à 33,36 $ et des échéances s’étalant du 10/02/2030 au 04/03/2035. Parmi celles-ci, 63 750 options (prix d’exercice 10,178 $) ont été réduites de 10 000, reflétant l’exercice. Les calendriers d’acquisition des attributions ultérieures s’étendent jusqu’en août 2032 et mars 2035, garantissant un alignement continu de la rémunération incitative avec la performance à long terme des actions.

Comme la vente des actions compense l’exercice des options, l’exposition économique de Prior via les actions ordinaires reste inchangée ; cependant, son exposition aux dérivés a légèrement diminué. L’utilisation d’un plan conforme à la règle 10b5-1 indique une exécution planifiée, ce qui peut atténuer les risques liés à la communication d’informations. Aucun autre initié ou administrateur n’a été impliqué, et le dépôt ne mentionne aucune nouvelle attribution d’options ni acquisition d’actions au-delà de ce qui est décrit.

Formular 4 Übersicht – Vita Coco Company, Inc. (COCO)

Die Chief Marketing Officer Jane Prior meldete eine kombinierte Ausübung von Optionen und Aktienverkauf zum 18.06.2025. Sie übte 10.000 nicht qualifizierte Aktienoptionen zum Ausübungspreis von 10,178 $ pro Aktie aus (Transaktionscode „M“) und erwarb unmittelbar dieselbe Anzahl an Stammaktien. Am selben Tag verkaufte sie 10.000 Aktien am offenen Markt im Rahmen eines vorab festgelegten Rule 10b5-1 Handelsplans (Transaktionscode „S“) zu einem gewichteten Durchschnittspreis von 35,116 $, in einer Spanne von 35,00 $ bis 35,33 $. Nach den Transaktionen bleibt Priors direkter Stammaktienbestand mit 134.188 Aktien unverändert.

Die Einreichung beschreibt auch Priors verbleibende Derivateposition: 169.479 ausgeübte und nicht ausgeübte Optionen aus acht Zuteilungen mit Ausübungspreisen von 10,178 $ bis 33,36 $ und Laufzeiten von 10.02.2030 bis 04.03.2035. Davon wurden 63.750 Optionen (Ausübungspreis 10,178 $) um 10.000 reduziert, was die Ausübung widerspiegelt. Die Vesting-Pläne für spätere Zuteilungen erstrecken sich bis August 2032 und März 2035 und gewährleisten eine fortlaufende Ausrichtung der Anreizvergütung an der langfristigen Aktienperformance.

Da der Aktienverkauf die Ausübung der Optionen ausgleicht, bleibt Priors wirtschaftliche Beteiligung am Stammkapital unverändert; jedoch verringerte sich ihre Derivateposition leicht. Die Nutzung eines Rule 10b5-1 Plans signalisiert eine vorab geplante Ausführung, was das Risiko von Fehlinterpretationen reduzieren kann. Keine weiteren Insider oder Direktoren waren involviert, und die Einreichung nennt keine neuen Optionszuteilungen oder Aktienerwerbe über die beschriebenen hinaus.

Positive
  • No net reduction in the insider’s direct common-stock holdings despite the sale, maintaining alignment with shareholders.
  • Transaction executed under a Rule 10b5-1 plan, signalling pre-planning and reducing concerns about adverse insider timing.
Negative
  • 10,000-share sale (≈7% of prior holdings) could be perceived as profit-taking, potentially a mild negative sentiment indicator.
  • Decrease in derivative position by 10,000 options slightly reduces future upside leverage.

Insights

TL;DR: CMO exercised & sold 10k shares; net share count flat, minor option rundown – neutral signal.

The 06/18/2025 Form 4 shows Jane Prior monetising 10,000 shares by exercising low-priced options ($10.178) and liquidating the shares at $35.116, locking in a spread without changing her direct ownership. Post-trade she still owns 134,188 shares, a sizeable stake that continues to align her with shareholders. The 10k sale represents roughly 7% of her previously held common stock and <1% of COCO’s float, thus limited market impact. The Rule 10b5-1 framework reduces the likelihood that the trade reflects short-term sentiment. The remaining 169k options, most of which are out-of-the-money or on long-dated vesting schedules, sustain long-term leverage. Given the absence of net share reduction and the pre-planned nature, I view the filing as neutral to investment thesis.

Panoramica del Modulo 4 – Vita Coco Company, Inc. (COCO)

La Chief Marketing Officer Jane Prior ha comunicato un esercizio abbinato di opzioni e una vendita di azioni datata 18/06/2025. Ha esercitato 10.000 opzioni su azioni non qualificate a un prezzo di esercizio di 10,178 $ per azione (codice transazione “M”), acquisendo immediatamente lo stesso numero di azioni ordinarie. Nello stesso giorno ha venduto 10.000 azioni sul mercato aperto nell’ambito di un piano di trading predefinito ai sensi della Regola 10b5-1 (codice transazione “S”) a un prezzo medio ponderato di 35,116 $, in un intervallo da 35,00 $ a 35,33 $. Dopo le transazioni, la detenzione diretta di azioni ordinarie di Prior rimane invariata a 134.188 azioni, senza variazioni nette.

Il documento dettaglia inoltre l’esposizione residua di Prior in strumenti derivati: 169.479 opzioni, sia maturate che non maturate, distribuite su otto concessioni con prezzi di esercizio compresi tra 10,178 $ e 33,36 $ e scadenze dal 10/02/2030 al 04/03/2035. Di queste, 63.750 opzioni (prezzo di esercizio 10,178 $) sono state ridotte di 10.000 in seguito all’esercizio. I piani di maturazione delle concessioni successive si estendono fino ad agosto 2032 e marzo 2035, garantendo un allineamento continuo della remunerazione incentivante con la performance azionaria a lungo termine.

Poiché la vendita delle azioni compensa l’esercizio delle opzioni, l’esposizione economica di Prior tramite il capitale ordinario rimane invariata; tuttavia, la sua esposizione derivata è diminuita leggermente. L’utilizzo di un piano secondo la Regola 10b5-1 indica un’esecuzione pianificata in anticipo, potenzialmente riducendo il rischio di segnali negativi. Nessun altro dirigente o amministratore è stato coinvolto e il documento non riporta nuove assegnazioni di opzioni né acquisizioni di azioni oltre a quelle descritte.

Resumen del Formulario 4 – Vita Coco Company, Inc. (COCO)

La Directora de Marketing Jane Prior reportó un ejercicio combinado de opciones y venta de acciones fechado el 18/06/2025. Ella ejerció 10,000 opciones sobre acciones no calificadas a un precio de ejercicio de $10.178 por acción (código de transacción “M”), adquiriendo inmediatamente la misma cantidad de acciones ordinarias. Ese mismo día vendió 10,000 acciones en el mercado abierto bajo un plan de trading preestablecido conforme a la Regla 10b5-1 (código de transacción “S”) a un precio promedio ponderado de $35.116, dentro de un rango de $35.00 a $35.33. Tras las transacciones, la tenencia directa de acciones ordinarias de Prior permanece en 134,188 acciones, sin cambios netos.

El informe también detalla la exposición restante de Prior en derivados: 169,479 opciones, tanto ejercibles como no ejercibles distribuidas en ocho concesiones con precios de ejercicio desde $10.178 hasta $33.36 y vencimientos entre el 10/02/2030 y el 04/03/2035. De estas, 63,750 opciones (precio de ejercicio $10.178) se redujeron en 10,000 debido al ejercicio. Los calendarios de adquisición de las concesiones posteriores se extienden hasta agosto de 2032 y marzo de 2035, asegurando una alineación continua de la compensación por incentivos con el rendimiento accionarial a largo plazo.

Dado que la venta de acciones compensa el ejercicio de opciones, la exposición económica de Prior a través del capital común no cambia; sin embargo, su exposición en derivados disminuyó modestamente. El uso de un plan conforme a la Regla 10b5-1 indica una ejecución planificada, lo que podría mitigar riesgos de señales negativas. Ningún otro directivo o director estuvo involucrado y el informe no menciona nuevas concesiones de opciones ni adquisiciones de acciones más allá de las descritas.

Form 4 개요 – Vita Coco Company, Inc. (COCO)

최고마케팅책임자 Jane Prior는 2025년 6월 18일자로 옵션 행사와 주식 매도 거래를 보고했습니다. 그녀는 10,000개의 비자격 주식매수선택권을 행사하였으며, 행사 가격은 주당 10.178달러였습니다(거래 코드 “M”). 즉시 동일 수량의 보통주를 취득했습니다. 같은 날, 그녀는 10,000주를 사전 계획된 Rule 10b5-1 거래계획에 따라 공개 시장에서 매도하였으며(거래 코드 “S”), 가중평균 가격은 35.116달러, 가격 범위는 35.00달러에서 35.33달러였습니다. 거래 후 Prior의 직접 보유 보통주 수는 134,188주로 순변동 없이 유지되었습니다.

보고서에는 Prior의 남은 파생상품 노출도 상세히 명시되어 있습니다: 8건의 부여를 통해 169,479개의 행사 가능 및 행사 불가능 옵션이 있으며, 행사가격은 10.178달러에서 33.36달러 사이이고 만료일은 2030년 2월 10일부터 2035년 3월 4일까지입니다. 이 중 63,750개 옵션(행사가격 10.178달러)은 행사로 인해 10,000개가 감소했습니다. 이후 부여된 옵션의 권리 취득 일정은 2032년 8월과 2035년 3월까지 이어져 장기 주가 성과와 인센티브 보상 간의 지속적인 정렬을 보장합니다.

주식 매도가 옵션 행사와 상쇄되었기 때문에 Prior의 보통주를 통한 경제적 노출은 변동이 없습니다; 다만 파생상품 노출은 다소 감소했습니다. Rule 10b5-1 계획의 사용은 사전 계획된 실행을 의미하며, 신호 위험 완화에 기여할 수 있습니다. 다른 임원이나 이사는 관여하지 않았으며, 보고서에는 본문에 설명된 것 외에 새로운 옵션 부여나 주식 취득 내역이 없습니다.

Présentation du Formulaire 4 – Vita Coco Company, Inc. (COCO)

La Directrice Marketing Jane Prior a déclaré une opération combinée d’exercice d’options et de vente d’actions datée du 18/06/2025. Elle a exercé 10 000 options d’achat d’actions non qualifiées à un prix d’exercice de 10,178 $ par action (code transaction « M »), acquérant immédiatement le même nombre d’actions ordinaires. Le même jour, elle a vendu 10 000 actions sur le marché libre dans le cadre d’un plan de trading préétabli selon la règle 10b5-1 (code transaction « S ») à un prix moyen pondéré de 35,116 $, dans une fourchette de 35,00 $ à 35,33 $. Après ces opérations, la détention directe d’actions ordinaires de Prior reste à 134 188 actions, inchangée sur une base nette.

Le dépôt détaille également l’exposition résiduelle de Prior aux dérivés : 169 479 options, acquises et non acquises, réparties sur huit attributions avec des prix d’exercice allant de 10,178 $ à 33,36 $ et des échéances s’étalant du 10/02/2030 au 04/03/2035. Parmi celles-ci, 63 750 options (prix d’exercice 10,178 $) ont été réduites de 10 000, reflétant l’exercice. Les calendriers d’acquisition des attributions ultérieures s’étendent jusqu’en août 2032 et mars 2035, garantissant un alignement continu de la rémunération incitative avec la performance à long terme des actions.

Comme la vente des actions compense l’exercice des options, l’exposition économique de Prior via les actions ordinaires reste inchangée ; cependant, son exposition aux dérivés a légèrement diminué. L’utilisation d’un plan conforme à la règle 10b5-1 indique une exécution planifiée, ce qui peut atténuer les risques liés à la communication d’informations. Aucun autre initié ou administrateur n’a été impliqué, et le dépôt ne mentionne aucune nouvelle attribution d’options ni acquisition d’actions au-delà de ce qui est décrit.

Formular 4 Übersicht – Vita Coco Company, Inc. (COCO)

Die Chief Marketing Officer Jane Prior meldete eine kombinierte Ausübung von Optionen und Aktienverkauf zum 18.06.2025. Sie übte 10.000 nicht qualifizierte Aktienoptionen zum Ausübungspreis von 10,178 $ pro Aktie aus (Transaktionscode „M“) und erwarb unmittelbar dieselbe Anzahl an Stammaktien. Am selben Tag verkaufte sie 10.000 Aktien am offenen Markt im Rahmen eines vorab festgelegten Rule 10b5-1 Handelsplans (Transaktionscode „S“) zu einem gewichteten Durchschnittspreis von 35,116 $, in einer Spanne von 35,00 $ bis 35,33 $. Nach den Transaktionen bleibt Priors direkter Stammaktienbestand mit 134.188 Aktien unverändert.

Die Einreichung beschreibt auch Priors verbleibende Derivateposition: 169.479 ausgeübte und nicht ausgeübte Optionen aus acht Zuteilungen mit Ausübungspreisen von 10,178 $ bis 33,36 $ und Laufzeiten von 10.02.2030 bis 04.03.2035. Davon wurden 63.750 Optionen (Ausübungspreis 10,178 $) um 10.000 reduziert, was die Ausübung widerspiegelt. Die Vesting-Pläne für spätere Zuteilungen erstrecken sich bis August 2032 und März 2035 und gewährleisten eine fortlaufende Ausrichtung der Anreizvergütung an der langfristigen Aktienperformance.

Da der Aktienverkauf die Ausübung der Optionen ausgleicht, bleibt Priors wirtschaftliche Beteiligung am Stammkapital unverändert; jedoch verringerte sich ihre Derivateposition leicht. Die Nutzung eines Rule 10b5-1 Plans signalisiert eine vorab geplante Ausführung, was das Risiko von Fehlinterpretationen reduzieren kann. Keine weiteren Insider oder Direktoren waren involviert, und die Einreichung nennt keine neuen Optionszuteilungen oder Aktienerwerbe über die beschriebenen hinaus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bertram Kenneth Robert

(Last) (First) (Middle)
C/O CAVA GROUP, INC.
14 RIDGE SQUARE NW, SUITE 500

(Street)
WASHINGTON DC 20016

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CAVA GROUP, INC. [ CAVA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CLO & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 S(1) 1,824 D $74.96(2) 58,907(3) D
Common Stock 06/16/2025 S(1) 374 D $76.11(4) 58,533(3) D
Common Stock 1,500 I By Spouse
Common Stock 195 I By Daughter
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
2. The price reported in column 4 represents the weighted average price of 65,026 shares of Common Stock sold by the broker on behalf of employees of the Issuer as a result of mandatory sell to cover transactions associated with the vesting of RSUs. These shares were sold in multiple transactions at prices ranging from $74.58 to $75.55, inclusive. The proceeds of all such sales were allocated to the employees, including the Reporting Person, on a pro rata basis. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
3. Includes unvested RSUs.
4. The price reported in column 4 represents the weighted average price of 13,402 shares of Common Stock sold by the broker on behalf of employees of the Issuer as a result of mandatory sell to cover transactions associated with the vesting of RSUs. These shares were sold in multiple transactions at prices ranging from $75.58 to $76.52, inclusive. The proceeds of all such sales were allocated to the employees, including the Reporting Person, on a pro rata basis. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
Remarks:
The reporting person states that this filing shall not be an admission that the reporting person is the beneficial owner of any of the securities reported herein as indirectly owned, and the reporting person disclaims beneficial ownership of such securities except to the extent of the reporting person's pecuniary interest therein.
/s/ Kenneth Robert Bertram 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many COCO shares did Jane Prior sell on 06/18/2025?

She sold 10,000 common shares at a weighted-average price of $35.116.

Did the insider’s total share ownership in Vita Coco (COCO) change?

No. After exercising and selling, Prior still holds 134,188 shares directly.

What was the exercise price of the options exercised by Jane Prior?

The options were exercised at $10.178 per share.

Was the COCO insider trade conducted under a Rule 10b5-1 plan?

Yes, the filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan.

How many derivative securities does Jane Prior hold after the reported transactions?

She retains 169,479 non-qualified stock options across multiple grants.
Cava Group, Inc.

NYSE:CAVA

CAVA Rankings

CAVA Latest News

CAVA Latest SEC Filings

CAVA Stock Data

10.36B
109.10M
8.32%
70.63%
5.25%
Restaurants
Retail-eating Places
Link
United States
WASHINGTON